Slide 1: Corporate presentation
Corporate presentation September 2016 For personal use only Cover sheet to be added – Simone AGM Presentation – October 2023 David Burton – Chairman, CEO dburton@compumedics.com.au David Lawson – Director, CFO dlawson@compumedics.com.au Sleep Diagnostics & Treatment - Neuro Diagnostics - Brain Resea
Slide 2: Purpose of the meeting
Purpose of the meeting For personal use only • Compumedics overview and key growth inflection points • Current breakout commercial traction and corresponding share value drivers • Market valuation gap – Compumedics v comparative companies and opportunity to re-rate the business
Slide 3: Corporate Video
For personal use only Corporate Video
Slide 4: Who is Compumedics?
Who is Compumedics? For personal use only Compumedics is a leading global medical technology company focused on: • Monitoring and diagnosing sleep disorders • Monitoring neurological disorders • Highly sophisticated brain research • Ultrasonic monitoring of blood flow through the brain #1 ASX FY24F
Slide 5: What has Compumedics done so far?
What has Compumedics done so far? For personal use only $ We have sold more than We sold sleep diagnostic We sell directly through We spend about 12% of 30,000 medical systems technology to NASA as our own businesses in revenues a year on around the world since part of the space shuttle Australia, U
Slide 6: Realisation opportunity – 2024 into 2025
Realisation opportunity – 2024 into 2025 For personal use only Key growth Inflection points and commercial traction are becoming evident for: • Somfit Australia– initial sales success in Australia with pharmacy-based market share at 75% estimated and initial Somfit/Nexus 360 SaaS revenues at $4.0m f
Slide 7: Shareholder value-gap inflection points
Shareholder value-gap inflection points For personal use only * Estimated Forecast market – pa annual CMP FY25 / Mkt growth - pa FY26 f’cast valuation Unique edge / positioning USD8.7bn 1 17.6% 1 USD5m to USD75m to Proven cloud-based innovative sleep *USA – Somfit / HST USD10m USD150m 2 technology c
Slide 8: Compumedics market valuation gap
Compumedics market valuation gap Compumedics is trading well below medical device multipliers let alone SaaS multipliers For personal use only for its emerging SaaS business. Value Gap Market Revenues Market Cap to (m) Cap (m) Revenues Itamar 51 538 10.5 Seer 11 220 20.0 Brightree 113 800 7.1 Propel
Slide 9: Compumedics valuation gap scenario
Compumedics valuation gap scenario For personal use only Compumedics SaaS based business driven by Somfit is only emerging and will be accelerated by our new sales leader hire in the key USA market. Possible scenario outcome 000 FY23 FY24 FY25 FY26 FY27 Somfit reimbursable HST SaaS scenario revenues
Slide 10: FY2024 – Trading update
FY2024 – Trading update For personal use only Core Business Update • More than $50m in Sales orders expected for FY24 • Over $46m in Revenue on target for FY24 • A profit for FY24 is anticipated on the back of strong sales performance Somfit Commercialisation Update • Over $4m in SaaS revenue for FY
Slide 11: Growth platform – core and inflection points
Growth platform – core and inflection points For personal use only FY23A FY24F FY25F FY26F FY27F Core - Base Sleep - USA expansion Sleep - Somfit/Nexus360 (SaaS) Neuro - EMG • Somfit USA – Somfit FDA achieved in December 2023, initial commercial contracts signed and execution of Global HST SaaS grow
Slide 12: Somfit inflection point
Somfittm inflection point For personal use only • Somfittm presents the next generation Home Sleep Test (HST) solution with incorporation of conventional vascular or respiratory-based sleep disordered breathing (SDB) monitoring, in addition to brain-signal-based sleep quality and architecture analys
Slide 13: MEG inflection point
MEG inflection point For personal use only • CMP Orion MEG is a global leading technology solution, based on it its unique Curry brain analytics platform, which has become the preeminent MEG user interface and analytics platform over a period of more than 2 decades. Several factors have now converge
Slide 14: DWL inflection point
DWL inflection point For personal use only • DWL is a global leader in TCD with over 11,000 installations world-wide, and is now looking to rapidly transition via partnership, or other impactful business realization mechanism, in the rapidly emerging DWL robotics/AI TCD market • Several factors have
Slide 15: Somfit – a new SaaS business moving from the sleep clinic eventually to the consumer
Somfit – a new SaaS business moving from the sleep clinic eventually to the consumer For personal use only Somfit builds on technical and clinical pedigree of Compumedics developed over the past 30+ years Somfit Consumer use Expand platform technology, in a consumer environment providing actionable
Slide 16: Somfit - Superior value proposition
Somfit - Superior value proposition For personal use only Somfit provides a more comfortable, convenient, and cost-effective way to assess and monitor sleep health. • Highly scalable: quality health SaaS business model. • Clinical grade at home device: Light and comfortable for the patient while ena
Slide 17: Somfit – Addressable market
Somfit – Addressable market For personal use only The addressable market for Somfit in Australia. • The reimbursable (Medicare Item Number 12250) addressable market in Australia is estimated at $6m being $40 studies pa at an average. This market is currently not accessible to Somfit, but Compumedics
Slide 18: MEG – The market
MEG – The market For personal use only How big is the market? • There are close to 200 active MEG labs globally. That number is growing every year. About ten new systems are sold each year. Three investment scenarios 1 Ongoing current traction 2 Major inflection where MEG scales up for brain functio
Slide 19: MEG – investment scenarios
MEG – investment scenarios For personal use only Potential revenue scenarios - USDm 30 25 20 15 10 5 0 FY2024 FY2025 FY2026 FY2027 As is Modest Accelerated
Slide 20: Investment opportunity
Investment opportunity For personal use only Inflection points and commercial traction are becoming evident for: • Somfit Australia– initial sales success in Australia with pharmacy-based market share at 75% estimated and initial Somfit/Nexus 360 SaaS revenues at $4.0m for FY24, with USA to add sign
Slide 21: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Compumedics Limited (CMP). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliabili
Slide 22: compumedics.com.au
For personal use only compumedics.com.au 23
Slide 23: Appendix
For personal use only Appendix Core business – Sleep Core business – Neuro Core business – DWL Revenue composition – FY23 What is MEG? compumedics.com.au
Slide 24: Core business unit - Sleep
Core business unit - Sleep For personal use only Sleep Diagnostics and Monitoring • Compumedics was founded as a sleep diagnostic and monitoring company in 1987 • Compumedics generates revenues of about $18.5m per year in this business, which includes initial SaaS revenues from our Somfit / Nexus 36
Slide 25: Core business unit - Neuro
Core business unit - Neuro For personal use only Neuro Diagnostics and brain research analytics • Compumedics expanded into neuro diagnostics in the early 2000’s and with the acquisition of Neuroscan, a leading brain analytics research business, in the USA in 2002 • Compumedics generates revenues of
Slide 26: Core business unit - DWL
Core business unit - DWL For personal use only Trans Cranial Doppler (TCD) • Compumedics expanded into TCD or ultra sonic monitoring of blood pressure through the brain with the acquisition of DWL in Germany in 2004 • Compumedics generates revenues of about $6.0m per year in this business • DWL has
Slide 27: Revenue Composition at $42.4m
Revenue Composition at $42.4m • 30 June 2023 – Geographic and product diversification serves us well For personal use only By geographic region By product/market Customer Consumables Care 8% Europe, USA, Brain - 10% 26% 28% Blood Flow Monitoring Sleep - 15% Clinical Diagnostics 32% Brain - Research
Slide 28: What is MEG ?
For personal use only What is MEG ?